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Lessons Learned During Recent Vaccine Filings
Outline
Regulatory challenges with vaccines
Managing Risk – the importance of planning
Approach to agency feedback during development
Managing activities during regulatory review
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Background
During 2004-2005 Merck submitted applications 








Challenges in vaccine development
Manufacturing complexity
Integration of clinical, process and analytical development
Relatively long development cycle
−New information may impact development plans
Changing regulatory environment
− Increasing emphasis on safety
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Managing Regulatory Risk 
The Importance of Planning
Planning during development
− Identifying key regulatory issues
−Developing a plan to address these issues
Planning the preparation of the file
−Well-organized dossier
−Ensuring key label statements are supported
Planning for activities during review
−Pre-filing checklist
−Challenge of global simultaneous submissions
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Identifying key regulatory questions/issues
What does the efficacy evaluation need to address?
Risk/benefit - sufficient benefit to justify use in healthy?
Precision of estimate – lower bound
Non-inferiority - clinically relevant equivalence margins
− How well understood is the quantitative relationship between 
immunogenicity and efficacy?
− Potential impact of decrease in efficacy on transmission
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Identifying key regulatory questions/issues
What does the safety evaluation need to address?
Risk/benefit - sufficiently safe to justify use in healthy?
Evaluation of uncommon AEs – power to detect
−What is a signal?  Issue of multiple comparisons
New information may change the scope/focus of the 
safety evaluation 
− Rotavirus vaccines and intussusception
Questions related to new technology
− New cell substrates – new adventitious agents
− Novel adjuvants – cascade effects?   autoimmunity?
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Identifying key regulatory questions/issues
“Non-traditional” efficacy measures
−Novel endpoints may be less familiar
−Need for agreement on how to measure efficacy
What is clinically relevant?
Endpoint validation
Surrogacy
−How to communicate to physicians and patients 
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Regulatory feedback during development
Refer to guidance when possible
Identify questions for agency feedback
Develop proposals for concurrence
Some questions may require iterative discussion as data 
become available
There may not be pre-defined answers to some questions 
− Potential need for broader discussion/input
Guidance may change as science evolves
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Regulatory feedback during development
Procedural aspects
−Formal feedback
US: PDUFA meetings, Special Protocol Assessment
EU: Scientific Advice
− Informal feedback
May be particularly useful for preclinical and CMC questions 
which are “non-standard”
May be useful in helping formulate questions for Scientific 
Advice
Workload issues at agencies – being judicious with what 
questions to ask
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Regulatory feedback during development
Examples of items for concurrence








−Demonstration of manufacturing consistency
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Regulatory feedback during development
Examples of items for concurrence
Analytical Development Plans
−Role/utility of characterization dependent on 
whether the product is well-characterized
−Rationalizing analytical development plan 
Purpose of each test, supporting data and interpretation as 
to why test is appropriate for chosen purpose
Integration of analytical, process and clinical development
−Product specifications versus characterization
−Comparability protocols 
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Managing Regulatory Risk 
The Importance of Planning
Planning during development
− Identifying key regulatory issues
−Developing a plan to address these issues
Planning the preparation of the file
−Well-organized dossier
−Ensuring key label statements are supported
Planning for activities during review
−Pre-filing checklist




−Update agencies on phase III results
−Status and timing of ongoing studies
−Agreement on content/format of application
High level – not a “pre-review” of data
Electronic submissions considerations





−Detailed review of facility information will be 
conducted by CBER onsite during PAI
Batch release
− Interactions with agencies performing batch 
release
−Discussion and selection of OMCL and TOI (EU)




−Early planning for post-licensure studies 
Evaluate product use in “real-world” setting
Detection of less common adverse events
−Linked databases
Important tool for evaluating rare AEs
Finite number of venues/investigators (who may have other 
commitments)
Local institutional/operational factors may impact on protocol 
design and timing – critical issue for PMC timing/compliance
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Timeline of Review Activities 
in the EU and US
Pre-BLA 
meeting



































Routinely convened for most new vaccines
−Under FDAAA, FDA needs to justify not having an ACM
External consultants asked by FDA to opine on adequacy 
of evidence supporting safety/efficacy
− AC may recommend additional studies pre- or post-licensure
Restrictive Conflict of Interest requirements
−Challenges identifying experts without conflicts




Use agency feedback during development to better 
understand the key issues for the benefit-risk evaluation
Some questions may require a broader discussion
New information may impact on requirements
The environment is changing
